Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma

The need for improved healthcare infrastructure for extranodal NK/T-cell lymphoma in Latin America

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results

High-fibre dietary intervention in precursor plasma cell disorders improves biomarkers of disease, may delay progression to myeloma

Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD

KRdc as induction therapy shows improved OS for NDMM patients

Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL

Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL

Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL

Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma